No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder

Molecular Psychiatry

Volumn 6, Issue 1, 2001, Pages 59-65

  Hamilton, S P ^a   Slager, S L ^a   Helleby, L ^a   Heiman, G A ^a   Klein, D F ^a   Hodge, S E ^a,b   Weissman, M M ^a,c   Fyer, A J ^a   Knowles, J A ^a,d  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c NONE   (United States)

^d NONE   (United States)

Author keywords

Candidate gene; Family based; Fluorescence polarization

Indexed keywords

ANTIPANIC AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ B RECEPTOR; MICROSATELLITE DNA;

ANXIETY NEUROSIS; ARTICLE; CONTROLLED STUDY; CORRELATION FUNCTION; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; DNA POLYMORPHISM; FAMILY STUDY; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; GENE EXPRESSION REGULATION; GENE LOCUS; GENETIC CODE; GENETIC LINKAGE; GENOTYPE; HAPLOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MOLECULAR MODEL; PANIC; PEDIGREE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM;

CHOLECYSTOKININ; FAMILY HEALTH; FLUORESCENCE POLARIZATION; HUMANS; LINKAGE (GENETICS); MICROSATELLITE REPEATS; PANIC DISORDER; POLYMORPHISM, GENETIC; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

EID: 0035138497     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000788     Document Type: Article

References (46)

1. The cross-national epidemiology of panic disorder
2. Panic disorder and agoraphobia
3. Familial aggregation and phenomenology of 'early-onset' (at or before age 20 years) panic disorder
4. Panic disorder with smothering symptoms: Evidence for increased risk in first-degree relatives
5. Panic disorder in women: A population-based twin study
6. Segregation analysis of panic disorder
7. New segregation analysis of panic disorder
8. Results of a genome-wide genetic screen for panic disorder
9. Functional promoter polymorphism of the human serotonin transporter: Lack of association with panic disorder
10. Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder
11. An association study between a transcriptional polymorphism in the serotonin transporter gene and panic disorder in a Japanese population
12. Missense mutation of the cholecystokinin B receptor gene: Lack of association with panic disorder
13. The genes encoding the 5HT1D alpha and 5HT1D beta receptors are unchanged in patients with panic disorder
14. 36CT with panic disorder
15. Neurobiology of panic disorder
16. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings
17. Cholecystokinin-tetrapeptide induces panic attacks in patients with panic disorder
18. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings
19. Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses
20. The panicogenic effects of cholecystokinin-tetra-peptide are antagonized by L-365.260, a central cholecystokinin receptor antagonist, in patients with panic disorder
21. Effect of Cl-988, a cholecystokinin-B receptor antagonist on lactate-induced panic
22. Placebo-controlled trial of the CCK-B antagonist, Cl-988, in panic disorder
23. The cholecystokinin-B receptor antagonist Cl-988 failed to affect CCK-4 induced symptoms in panic disorder patients
24. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients
25. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder
26. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks
27. Investigation of cholecystokinin system genes in panic disorder
28. Schedule for Affective Disorders and Schizophrenia-Lifetime Version Modified for the Study of Anxiety Disorders (SADS-LA): Rationale and conceptual development
29. Genetic linkage study of panic: Clinical methodology and description of pedigrees
30. Dinucleotide repeat polymorphism at the human CCKBR locus
31. Fluorescence polarization in homogeneous nucleic acid analysis
32. Faster sequential genetic linkage computations
33. Avoiding recomputation in linkage analysis
34. The available possibilities to analyze data of polygenic disease statistically
35. Transmission test for linkage disequilibrium: The insulin gene region and insulin-dependent diabetes mellitus (IDDM)
36. A powerful likelihood method for the analysis of linkage disequilibrium between trait loci and one or more polymorphic marker loci
37. A haplotype-based 'haplotype relative risk' approach to detecting allelic associations
38. Testing for segregation distortion in the HLA complex
39. Monte Carlo tests for associations between disease and alleles at highly polymorphic loci
40. Transcriptional regulation of the human cholecystokinin gene: Composite action of upstream stimulatory factor, Sp1, and members of the CREB/ATF-AP-1 family of transcription factors
41. Regulation of CCK mRNA expression in the rat brain by stress and treatment with sertraline, a selective serotonin re-uptake inhibitor
42. Linked polymorphisms upstream of exons 1 and 2 of the human cholecystokinin gene are not associated with schizophrenia or bipolar disorder
43. No association between C-45T polymorphism in the Sp1 binding site of the promoter region of the cholecystokinin gene and alcoholism
44. Genetic association between alcohol withdrawal symptoms and polymorphism of CCK gene promoter